Webinar Part 2: Drs. Dale Bredesen and Craig Tanio Share 2025 Randomized Controlled Trial Results

In Part 2 of an Apollo Health webinar, founder and Chief Scientific Officer Dr. Dale Bredesen was joined by clinical investigator Dr. Craig Tanio to discuss clinical insights from the 2025 Randomized Clinical Trial evaluating a precision medicine approach for mild cognitive impairment and early Alzheimer’s disease.

The conversation focused on how a multi-phase, personalized intervention strategy addressing lifestyle foundations, metabolic and inflammatory drivers, and targeted neurological therapies was associated with statistically significant cognitive improvements, reinforcing the potential of comprehensive precision medicine in clinical practice.

Watch here: